How effective is erdafitinib in treating pancreatic cancer?

Erdafitinib has shown remarkable results in the treatment of pancreatic cancer. As an FGFR1-4 tyrosine kinase inhibitor, erdafitinib uses the concept of precision medicine to attack tumor cells with FGFR mutations, thereby achieving the purpose of effectively controlling the disease.

In multiple clinical studies, the performance of erdafitinib in the treatment of pancreatic cancer has been impressive. Especially for those pancreatic cancer patients with FGFR fusion, the therapeutic effect of erdafitinib is more significant. There is a case report showing that a frail 68-year-old female patient with stage IV pancreatic cancer achieved a durable complete response after treatment with erdafitinib. This is not only reflected in the rapid decline and return to normal of the patient's tumor markers, but also in the complete regression of the primary tumor and metastatic lesions.

In addition, in larger studies, erdafitinib also demonstrated broad efficacy against pancreatic cancer. In a study involving 217 patients with different tumors, the objective response rate of erdafitinib for pancreatic cancer exceeded 50%, and the disease control rate was as high as 94%. These data strongly illustrate the effectiveness of erdafitinib in the treatment of pancreatic cancer.

In general, erdafitinib, as a representative drug of precision medicine, has shown significant efficacy in the treatment of pancreatic cancer. By inhibiting FGFR tyrosine kinase, it effectively blocks the growth and spread of tumor cells, providing new treatment options and hope for patients with pancreatic cancer. However, it is important to note that each patient's specific situation and response may vary, so when treated with erdafitinib, an individualized treatment plan should be developed based on the patient's specific situation and the recommendations of the physician.